| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
BMY
Bristol-Myers Squibb
|
Oct 29, 2026 | BUY |
Buy
-2.2% avg upside
42 analysts
|
$75.00
20.12% Upside
|
+1.4% | · |
|
KYMR
Kymera Therapeutics
|
Oct 28, 2026 | BUY |
Strong Buy
-9.6% avg upside
39 analysts
|
$170.00
34.22% Upside
|
+5.4% | · |
|
ACRS
Aclaris Therapeutics
|
Oct 28, 2026 | BUY |
Strong Buy
+155.5% avg upside
16 analysts
|
$12.00
202.24% Upside
|
-1.3% | · |
|
ARQT
Arcutis Biotherapeutics
|
Oct 19, 2026 | BUY |
Strong Buy
+28.9% avg upside
15 analysts
|
$44.00
37.12% Upside
|
-14.1% | · |
|
RYTM
Rhythm Pharmaceuticals
|
Oct 19, 2026 | BUY |
Strong Buy
+39.2% avg upside
23 analysts
|
$143.00
54.57% Upside
|
+24.3% | · |
|
PCVX
Vaxcyte
|
Oct 18, 2026 | BUY |
Strong Buy
+77.8% avg upside
15 analysts
|
$125.00
101.59% Upside
|
-0.3% | · |
|
MBX
MBX Biosciences, Inc.
|
Oct 12, 2026 | BUY |
Strong Buy
+53.5% avg upside
14 analysts
|
$150.00
168.41% Upside
|
+4.8% | · |
|
SGMT
Sagimet Biosciences, Inc. Class A
|
Oct 01, 2026 | BUY |
Strong Buy
+194.3% avg upside
17 analysts
|
$26.00
162.05% Upside
|
+10.9% | · |
|
IVA
Inventiva
|
Sep 28, 2026 | BUY |
Strong Buy
+350.3% avg upside
17 analysts
|
$14.00
283.57% Upside
|
+5.1% | · |
|
LLY
Eli Lilly & Co
|
Sep 17, 2026 | BUY |
Strong Buy
-16.7% avg upside
50 analysts
|
$1284.00
9.37% Downside
|
+23.8% | · |
|
TENX
Tenax Therapeutics
|
Aug 31, 2026 | HOLD |
Buy
+1239.2% avg upside
9 analysts
|
— | -3.3% | · |
|
AMLX
Amylyx Pharmaceuticals Inc
|
Aug 26, 2026 | BUY |
Strong Buy
+31.6% avg upside
14 analysts
|
$57.00
97.48% Upside
|
-20.5% | · |
|
MLYS
Mineralys Therapeutics, Inc.
|
Aug 12, 2026 | BUY |
Strong Buy
+150.9% avg upside
12 analysts
|
$52.00
186.10% Upside
|
-45.2% | · |
|
SEPN
Septerna, Inc.
|
Aug 11, 2026 | BUY |
Strong Buy
+17.7% avg upside
12 analysts
|
$51.00
15.92% Upside
|
-12.2% | · |
|
ARCT
Arcturus Therapeutics
|
Aug 06, 2026 | HOLD |
Buy
+175.7% avg upside
36 analysts
|
— | +46.7% | · |
|
SNY
Sanofi
|
Jul 09, 2026 | HOLD |
Strong Buy
+64.5% avg upside
20 analysts
|
— | +10.3% | · |
|
GB:AZN
AstraZeneca
|
Jul 09, 2026 | BUY |
Strong Buy
+7.8% avg upside
28 analysts
|
$16200.00
16.04% Upside
|
+8.6% | · |
|
GENB
Generate Biomedicines, Inc.
|
Jun 24, 2026 | BUY |
Strong Buy
+85.4% avg upside
6 analysts
|
$30.00
107.49% Upside
|
-22.1% | · |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
May 07, 2026 | BUY |
Strong Buy
+373.3% avg upside
17 analysts
|
$140.00
540.19% Upside
|
-50.4% | · |
|
FR:SAN
Sanofi
|
Oct 08, 2025 | BUY |
Strong Buy
+21.3% avg upside
30 analysts
|
$101.00
26.66% Upside
|
-11.0% | · |
|
NVO
Novo Nordisk
|
Apr 17, 2025 | HOLD |
Hold
+188.3% avg upside
26 analysts
|
— | -26.9% | · |
|
ALT
Altimmune
|
Apr 03, 2025 | HOLD |
Strong Buy
+1191.4% avg upside
20 analysts
|
— | -25.1% | · |
|
GB:0QIU
Novo Nordisk
|
Jan 17, 2025 | BUY |
Hold
+52.9% avg upside
29 analysts
|
$798.00
199.99% Upside
|
· | · |
|
GB:GSK
GlaxoSmithKline
|
Oct 31, 2024 | HOLD |
Hold
+5.2% avg upside
26 analysts
|
— | +27.9% | · |
|
GSK
GlaxoSmithKline
|
Oct 31, 2024 | HOLD |
Hold
-14.7% avg upside
20 analysts
|
— | +33.3% | · |
|
MRK
Merck & Company
|
Jan 29, 2024 | BUY |
Strong Buy
-3.5% avg upside
44 analysts
|
$130.00
13.08% Downside
|
-16.8% | · |
|
ZLAB
Zai Lab
|
Oct 14, 2022 | BUY |
Strong Buy
+170.4% avg upside
13 analysts
|
$83.00
276.17% Upside
|
-12.2% | · |
|
IVVD
Invivyd
|
Dec 15, 2021 | HOLD |
Buy
+1291.0% avg upside
8 analysts
|
— | -74.7% | · |
|
DE:MRK
Merck KGaA
|
Dec 07, 2021 | HOLD |
Buy
-7.2% avg upside
34 analysts
|
— | -20.0% | · |
|
CH:NOVN
Novartis AG
|
Feb 25, 2020 | HOLD |
Hold
-15.0% avg upside
32 analysts
|
— | -6.0% | · |
|
NVS
Novartis
|
Oct 08, 2018 | HOLD |
Hold
-16.1% avg upside
24 analysts
|
— | +15.3% | · |
|
ARDX
Ardelyx
|
Oct 17, 2017 | BUY |
Strong Buy
+324.3% avg upside
21 analysts
|
$13.00
329.05% Upside
|
-28.5% | · |
|
PFE
Pfizer
|
Sep 08, 2016 | HOLD |
Buy
+9.2% avg upside
46 analysts
|
$37.00
21.27% Upside
|
+2.2% | · |
|
NPKI
NPK International
|
Aug 24, 2016 | BUY |
Strong Buy
+169.8% avg upside
12 analysts
|
$108.00
1055.10% Upside
|
-0.8% | · |
|
KYNB
Kyntra Bio
|
Aug 09, 2016 | BUY |
Buy
+615.8% avg upside
17 analysts
|
$52.00
1037.85% Upside
|
· | · |
|
REGN
Regeneron
|
Jul 15, 2016 | BUY |
Strong Buy
-12.1% avg upside
60 analysts
|
— | +35.1% | · |
|
AMGN
Amgen
|
Jul 15, 2016 | HOLD |
Buy
-29.9% avg upside
57 analysts
|
— | +11.4% | · |
|
ALNY
Alnylam Pharma
|
Jul 15, 2016 | BUY |
Strong Buy
+76.3% avg upside
53 analysts
|
— | +22.1% | · |
|
JNJ
Johnson & Johnson
|
Jun 14, 2016 | BUY |
Strong Buy
-9.1% avg upside
40 analysts
|
$125.00
54.19% Downside
|
+16.4% | · |
|
AGIO
Agios Pharma
|
Jun 13, 2016 | HOLD |
Strong Buy
+99.0% avg upside
30 analysts
|
$56.00
83.37% Upside
|
-2.4% | · |
|
CLDX
Celldex
|
Mar 07, 2016 | HOLD |
Strong Buy
+42.9% avg upside
28 analysts
|
$4.00
86.77% Downside
|
-8.7% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.